NasdaqGM - Delayed Quote USD

Maze Therapeutics, Inc. (MAZE)

12.79

+0.79

+(6.58%)

At close: February 18 at 4:00:00 PM EST

Maze Therapeutics doses first subject in Phase II AKD treatment trial

The proof-of-concept interim data is expected in the first quarter of 2026.

Clinical Trials Arena 8 days ago

MAZE
+6.58%
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, today announced the first patient has been dosed in the company’s Phase 2 clinical trial, the HORIZON Study, of MZE829 in patients with APOL1 kidney disease (AKD). MZE829 is an oral, small m

GlobeNewswire 11 days ago

MAZE
+6.58%
Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs

(Bloomberg) -- A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care first-time share sales since October.Most Read from BloombergManhattan’s Morning Commute Time Drops With New Congestion TollHow the 2025 Catholic Jubilee Is Reshaping RomeTrump Paves the Way to Deputize Local Police on ImmigrationHousing Aid Uncertain After Trump’s Spending Freeze MemoTrump's Federal Funding Pause Threatens State Financials Metsera Inc. raised $275

Bloomberg 18 days ago

MTSR
+4.91%
MAZE
+6.58%
Maze Therapeutics Announces Pricing of Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, today announced the pricing of its upsized initial public offering of 8,750,000 shares of its common stock at a public offering price of $16.00 per share. The gross proceeds from the

GlobeNewswire 19 days ago

MAZE
+6.58%
Metsera, Maze secure combined $415 million in IPOs

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go public.

BioPharma Dive 19 days ago

MTSR
+4.91%
MAZE
+6.58%

Performance Overview

Return	MAZE	S&P 500
YTD	-20.66%	+4.22%
1-Year	-20.66%	+22.46%
3-Year	-20.66%	+40.95%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics doses first subject in Phase II AKD treatment trial

Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs

Maze Therapeutics Announces Pricing of Upsized Initial Public Offering

Metsera, Maze secure combined $415 million in IPOs

Performance Overview